Chardan Capital Forecasts Ocugen FY2025 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Equities research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Ocugen in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will earn ($0.25) per share for the year. Chardan Capital has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Chardan Capital also issued estimates for Ocugen’s FY2026 earnings at ($0.27) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Ocugen in a report on Thursday, March 6th.

Ocugen Stock Up 3.4 %

Shares of NASDAQ:OCGN opened at $0.74 on Thursday. The firm has a market capitalization of $215.80 million, a P/E ratio of -4.11 and a beta of 3.88. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The stock has a 50 day moving average price of $0.67 and a 200-day moving average price of $0.84. Ocugen has a 52-week low of $0.52 and a 52-week high of $2.08.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. During the same period in the prior year, the firm earned ($0.03) earnings per share.

Hedge Funds Weigh In On Ocugen

A number of institutional investors and hedge funds have recently made changes to their positions in OCGN. BNP Paribas Financial Markets bought a new stake in shares of Ocugen in the 4th quarter worth approximately $30,000. Ameriprise Financial Inc. bought a new stake in Ocugen in the fourth quarter worth $30,000. Virtu Financial LLC purchased a new stake in shares of Ocugen in the fourth quarter worth $32,000. Tower Research Capital LLC TRC increased its holdings in shares of Ocugen by 309.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock valued at $32,000 after acquiring an additional 30,120 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Ocugen in the 4th quarter worth about $40,000. Institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.